https://ir.renovorx.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/renovorx/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.renovorx.com/news-events/press-releases/detail/180/renovorx-reports-record-third-quarter-2026-revenue-exceeding-1-million Thu, 05 Nov 26 16:05:00 -0500 https://ir.renovorx.com/news-events/press-releases/detail/180/renovorx-reports-record-third-quarter-2026-revenue-exceeding-1-million https://ir.renovorx.com/news-events/press-releases/detail/179/renovorx-to-participate-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health-services-forum Wed, 28 Oct 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/179/renovorx-to-participate-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health-services-forum https://ir.renovorx.com/news-events/press-releases/detail/178/renovorx-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026 Thu, 22 Oct 26 08:45:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/178/renovorx-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026 https://ir.renovorx.com/news-events/press-releases/detail/177/renovorx-advances-tamp-into-borderline-resectable-pancreatic-cancer-with-first-patient-enrolled-in-investigator-initiated-prism-tamp-trial Wed, 07 Oct 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/177/renovorx-advances-tamp-into-borderline-resectable-pancreatic-cancer-with-first-patient-enrolled-in-investigator-initiated-prism-tamp-trial https://ir.renovorx.com/news-events/press-releases/detail/176/renovorx-announces-peer-reviewed-publication-highlighting-the-tamp-platforms-potential-to-improve-chemotherapeutic-delivery-for-locally-advanced-pancreatic-cancer Thu, 01 Oct 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/176/renovorx-announces-peer-reviewed-publication-highlighting-the-tamp-platforms-potential-to-improve-chemotherapeutic-delivery-for-locally-advanced-pancreatic-cancer https://ir.renovorx.com/news-events/press-releases/detail/175/renovorx-to-present-at-h-c-wainwright-28th-annual-global-investment-conference-september-14th-16th Wed, 02 Sep 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/175/renovorx-to-present-at-h-c-wainwright-28th-annual-global-investment-conference-september-14th-16th https://ir.renovorx.com/news-events/press-releases/detail/174/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pkpd-data-supporting-tamp-platforms-targeted-drug-delivery-in-locally-advanced-pancreatic-cancer Tue, 25 Aug 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/174/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pkpd-data-supporting-tamp-platforms-targeted-drug-delivery-in-locally-advanced-pancreatic-cancer https://ir.renovorx.com/news-events/press-releases/detail/173/renovorx-regains-compliance-with-nasdaq-minimum-bid-price-requirement Fri, 21 Aug 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/173/renovorx-regains-compliance-with-nasdaq-minimum-bid-price-requirement https://ir.renovorx.com/news-events/press-releases/detail/172/renovorx-receives-notice-of-allowance-for-new-u-s-patent-covering-renovocath-an-advanced-dual-occlusion-catheter-for-targeted-therapeutic-drug-delivery-for-cancer-treatment Thu, 20 Aug 26 08:30:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/172/renovorx-receives-notice-of-allowance-for-new-u-s-patent-covering-renovocath-an-advanced-dual-occlusion-catheter-for-targeted-therapeutic-drug-delivery-for-cancer-treatment https://ir.renovorx.com/news-events/press-releases/detail/171/renovorx-reports-record-second-quarter-2026-results-driven-by-accelerating-commercial-adoption-and-61-sequential-quarterly-revenue-growth Wed, 12 Aug 26 16:05:00 -0400 https://ir.renovorx.com/news-events/press-releases/detail/171/renovorx-reports-record-second-quarter-2026-results-driven-by-accelerating-commercial-adoption-and-61-sequential-quarterly-revenue-growth